排序方式: 共有39条查询结果,搜索用时 15 毫秒
1.
目的:比较加替沙星在正常与肝损害模型家犬体内的药动学。方法:家犬腹腔注射四氯化碳溶液,建立肝损害模型;给药 后分别在规定时间点取样,以高效液相色谱法测定各时间点加替沙星血药浓度,利用3p87软件计算其药动学参数,并与正常家犬 比较。结果:加替沙星在正常家犬与肝损害模型家犬体内分布均呈一室模型,tmax分别为(2.35±0.75)h、(1.06±0.32)h,t1/2ke分 别为(8.38±2.03)h、(8.91±1.21)h,Cmax分别为(2.29±0.11)、(2.63±0.07)mg/L,AUC分别为(33.82±6.78)、(36.80± 4.67)(μg·h)/ml,经t检验无显著性差异(P>0.05)。结论:加替沙星在正常与肝损害模型家犬体内药动学比较无显著性影响。 相似文献
2.
3.
目的:比较两种奥美拉唑肠溶胶囊的人体相对生物利用度,并做出生物等效性评价,以考察试验制剂的药品质量.方法:按照两制剂两周期随机交叉设计,19名男性健康志愿者单剂量口服试验胶囊(20mg×2)和参比胶囊(40mg).采用HPLC法测定血浆奥美拉唑浓度.运用DAS2.0软件计算药动学参数,并进行统计学分析.结果:单剂量口服40mg的奥美拉唑肠溶试验胶囊和参比胶囊后,AUC0?12分别为(3184.81±2055.44)ng·h·ml-1和(3062.46±1957.74)ng·h·ml-1,AUC0?8分别为(3361.55±2370.29)ng·h·ml-1和(3186.89±2042.69)ng·h·ml-1;Cmax分别为(1066.44±482.99)ng·ml-1和(1072.99±472.30)ng·ml-1;Tmax分别为(2.50±0.82)h和(2.37±0.72)h;受试胶囊对参比胶囊平均相对生物利用度为(107.33±23.44)%.结论:试验胶囊与参比胶囊具生物等效性. 相似文献
4.
Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPⅡb/Ⅲa antagonist which may be useful in the treatment and prevention of acute coronary syndromes. The pharmacokinetics and pharmacodymanic (inhibition of platelet aggregation) effects, and tolerability of batifiban were investigated in healthy subjects following single bolus injection with doses of 55, 110, or 220 μg/kg, or multiple doses of an bolus followed intravenous infusion for 24 h (180 μg/kg plus 2.0 μg/minokg, and 220 μg/kg plus 2.5μg/minokg) in this phase I clinical trial. Plasma levels of batifiban and areas under the curve were found to be proportional to doses. Batifiban was rapidly eliminated with a half-life of approximately 2.5 h. Significant differences were noted for plasma levels of batifiban and areas under the curve between males and females. No significant differences in the terminal half-life were found between males and females. Batifiban reversibly inhibited ex vivo platelet aggregation in a dose- and concentration-dependent manner, consistent with its mechanism as a GPⅡ b/Ⅲa antagonist. Single and multiple intravenous doses of batifiban were found to be safe and well tolerated in healthy subjects. These results support a bolus injection plus intravenous infusion regimen of batifiban for the treatment and prevention of acute coronary syndromes. 相似文献
5.
目的:研究吗替麦考酚酯软胶囊与吗替麦考酚酯胶囊在健康人体内的相对生物利用度及药动学,评价2种制剂的生物等效性。方法:采用双周期随机交叉设计,20名男性健康志愿者单剂量口服试验软胶囊或参比胶囊4粒(每粒0.25g),以高效液相色谱法测定血浆中霉酚酸(MPA)浓度。运用DAS2.0软件处理血药浓度数据和计算药动学参数,对2种制剂做出生物等效性评价。结果:受试者口服1.0g吗替麦考酚酯软胶囊试验药或参比胶囊,其AUC0→t分别为(69.95±14.13)、(66.95±19.05)μg·h·mL-1,AUC0→∞分别为(85.18±20.51)、(77.39±23.78)μg·h·mL-1,Cmax分别为(31.26±13.09)、(31.90±14.45)μg·mL-1,tmax分别为(0.875±0.358)、(0.775±0.291)h,t1/2分别为(20.342±12.546)、(18.837±11.579)h。20名健康志愿者单剂量口服吗替麦考酚酯软胶囊试验药的相对生物利用度为(109.6±26.9)%。结论:试验软胶囊与参比胶囊具有生物等效性。 相似文献
6.
目的:观察女贞叶乙醇提取物对鹌鹑高脂血症的影响.方法:用外源性胆固醇和高脂饲料复制鹌鹑高脂血症模型,并诱发其肝脂肪变性,分为正常对照组、高脂模型组、脂必妥组(3 g·kg-1)、女贞叶乙醇提取物高、中、低组(1.5,3,6g·kg-1),给药4周.分别测定各组血清甘油三酯(TG)、胆固醇(CHO)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)的含量,并进行鹌鹑肝脂肪变性的病理组织学检查.结果:女贞叶乙醇提取物低剂量能降低血清TG(P <0.05);中、高剂量能明显降低血清TG,CHO(P <0.01),中、高剂量降低血清LDL-C(P<0.05,P<0.01),高剂量组能明显升高血清HDLC(P<0.01).给予女贞叶乙醇提取物后,鹌鹑肝系数明显减轻(P<0.01),肝中脂肪空泡数明显减少(P<0.01).结论:女贞叶乙醇提取物具有明显的防治鹌鹑高脂血症和肝脂肪变性的作用. 相似文献
7.
8.
The current study was designed to determine the safety, tolerability and pharmacokinetic parameters of recombinant human parathyroid hormone [rhPTH (1-84)] used for the treatment of osteoporosis. In the single-dose format pharmacokinetic study, thirty-six healthy male volunteers received three dose levels of rhPTH (1-84) subcutaneously: 1, 2, and 4 μg/kg. The blood was timing drawn and the serum concentration of rhPTH (1-84) was determined by enzyme linked immunosorbent assay (ELISA). Serum concentration-time curves of PTH (1-84) exhibited a double-peak pattern, the first peak appearing about 10 to 30 min after administration and the second peak occurring about 1.5 to2 h after administration. Serum terminal half-time of PTH (1-84) was approximately 2 h. The parameters indicated the serum levels were directly proportional to the administered dose, with the mean Cmax and AUC0_24 ranging from approximately 543.47 to 1845 pg/mL and 2358.6 to 9232.12 pg.h.mL^-1 over the dose range. The drug was well tolerated, the clinical symptoms were generally mild and of short duration. 相似文献
9.
目的 制备白及胶微球并探讨主要影响因素. 方法 采用乳化、冷凝固化、化学交联技术首次制备出白及胶微球,考察化学交联剂浓度和交联时间对微球影响, 通过对微球吸水率检测其溶胀度;研究微球与红细胞在37 ℃放置24 h, 观察红细胞的形态研究微球的血液相容性;采用60Co进行照射灭菌. 结果 制备的白及胶微球平均粒径为54.36 μm , 粒径范围50~90 μm占总数的78.37 %; 初步确定化学交联剂浓度为3%, 交联时间2 h;微球在pH值=7.4的缓冲液中有一定的溶胀性; 血液相容性良好. 2.5×10 4Gy 的60Co可以达到灭菌的要求. 结论 通过正交实验获得的制备工艺不仅可以制备临床需要的白及胶微球, 同时也为制备白及胶含药微球提供参考的实验条件. 相似文献
10.